NCT01947881
Completed
Not Applicable
Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)
Association for Innovation and Biomedical Research on Light and Image1 site in 1 country71 target enrollmentJanuary 2014
ConditionsDiabetic Macular Edema
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetic Macular Edema
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Enrollment
- 71
- Locations
- 1
- Primary Endpoint
- Central Retinal Thickness (Change from screening)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to identify Diabetic Macular Edema (DME) characteristics in eyes that show different response to treatment with anti-VEGF (vascular endothelial growth factor) injections of Lucentis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with 40 years of age or older.
- •Type 2 Diabetes Mellitus.
- •Glycosylated hemoglobin (HbA1C) ≤ 12% at screening visit.
- •Presence of clinically significant DME involving the center (fovea) diagnosed in at least one eye that is eligible for anti-VEGF treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at screening visit, will be selected as the study eye.
- •Visual impairment due to DME with BCVA ≥ 39 letters and ≤ 73 letters (≥ 20/160 and ≤ 20/40).
- •Central subfield thickness ≥ 300µm.
Exclusion Criteria
- •Presence of any other ocular disease than DME in the study eye that may confound study results, such as Proliferative Retinopathy.
- •Previous treatment with vitrectomy or intravitreous injections of triancinolone or anti-VEGF drugs in the study eye.
- •Any previous laser photocoagulation (panretinal or focal) in the study eye within 6 months prior to inclusion in this study.
- •Active intraocular inflammation (grade trace or above) in either eye at screening visit.
- •Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at screening visit.
- •Important refractive errors (myopia \> 6D) or opacification of clear media that interferes with images evaluation.
- •Patients with renal failure or other systemic conditions which, in the opinion of the investigator, would preclude schedule study visits, completion of the study or a safe administration of study medication.
- •Other criteria that in the opinion of the investigator should condition the evaluation purposed.
Outcomes
Primary Outcomes
Central Retinal Thickness (Change from screening)
Time Frame: Change from Screening at 3 Months
Measured by Spectral Domain Optical Coherence Tomography (OCT)
Presence of OCT diffuse macular edema (without cyst formation) (change from screening)
Time Frame: Change from Screening at 3 Months
Presence of neurosensorial retinal detachment. (change from screening)
Time Frame: Change from Screening at 3 Months
Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)
Time Frame: Change from Screening at 3 Months
Presence and extension of capillary occlusion (change from screening)
Time Frame: Change from Screening at 3 Months
Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening)
Time Frame: Change from Screening at 3 Months
Secondary Outcomes
- Best Corrected Visual Acuity (BCVA) (Change from screening)(Change from Screening at 3 Months)
- Central Retinal Thickness (change from screening)(Change from Screening at 6 Months)
- Presence (and location) of cysts in the retinal layers (change from screening)(Change from Screening at 6 Months)
- Presence of OCT diffuse macular edema (without cyst formation) (change from screening)(Change from Screening at 6 months)
- Presence of neurosensorial retinal detachment. (change from screening)(Change from Screening at 6 Months)
- Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening)(Change from Screening at 6 months)
- Presence and extension of capillary occlusion (change from screening)(Change from Screening at 6 Months)
- Area of macular leakage (intraretinal fluid volume and retinal thickness) (change from screening)(Change from Screening at 6 Months)
- Best Corrected Visual Acuity (change from screening)(Change from Screening at 6 Months)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Screening For Diabetic Macular Edema Among Diabetic Patients Using Optical Coherence TomographyDiabetic Macular EdemaNCT03240458Assiut University100
Unknown
Not Applicable
Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak RepublicDiabetic Macular EdemaDiabetic RetinopathyNCT02063321Emil Martinka762
Completed
Not Applicable
Imaging Parameters and DME Treatment ResponseDiabetic Macular EdemaDiabetic RetinopathyNCT02637245Duke University32
Completed
Not Applicable
Retinal Thickness Analysis Using Optical Coherence TomographyDiabetic RetinopathyNCT00797134Association for Innovation and Biomedical Research on Light and Image45
Completed
Not Applicable
Describing Patient With DME, Their Patient Journey and Disease ProgressionDiabetic Macular EdemaNCT05966753Boehringer Ingelheim221,004